RAPT — RAPT Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
RAPT Therapeutics Inc (RAPT) is a biotechnology company listed on NASDAQ. It is led by Brian Russell Wong M.D., Ph.D., based in 561 Eccles Avenue, South San Francisco, CA, United States, 94080, with about 67 employees. RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Net income was -$52.4M. RAPT currently screens at market cap $132.1M.
Use this RAPT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RAPT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RAPT SEC filings page. Lician reads the product cache first so this HTML stays unique to RAPT Therapeutics Inc even when a live quote feed is slow.
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
RAPT Key Statistics
Market Cap
$132.08M
EPS
-$3.19
Revenue
$0.00
Net Income
-$129.87M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
67
RAPT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.53M | $3.81M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$129.87M | -$116.80M | -$83.84M | -$69.20M |
| EPS (Diluted) | -$3.19 | -$3.05 | -$2.58 | -$2.53 |
Total Assets
$240.32M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$169.74M
Operating Cash Flow
-$83.30M
Free Cash Flow
$0.00
RAPT Therapeutics Inc Company Information
- CEO, President & Director
- Brian Russell Wong M.D., Ph.D.
- Headquarters
- 561 Eccles Avenue, South San Francisco, CA, United States, 94080
- Website
- www.rapt.com
- Phone
- 650-489-9000
- IPO / Founded
- 2019-10-31
- Sector
- Healthcare
- Industry
- Biotechnology